Clinical trials · Texas
Chronic Myeloid Leukemia clinical trials in Texas
We’re tracking 65 recruiting chronic myeloid leukemia studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06236724RecruitingPhase 2
Asciminib for newly diagnosed chronic myeloid leukemia
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Houston, TexasAges 18 years+ - NCT06423911RecruitingPhase 3
Olverembatinib for chronic-phase CML with prior treatment
This trial tests a new oral drug, olverembatinib, for people with chronic-phase CML that has not responded well to at least two other TKIs, or who have a specific mutation (T315I). The goal is to see if it can control the leukemia better.
Houston, TexasAges 18–99 - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Houston, TexasAges 18 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Dallas, TexasAges 18 years+ - NCT06817720RecruitingPhase 2
Olverembatinib for newly diagnosed chronic phase CML
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Houston, TexasAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Houston, TexasAges 18–66 - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Houston, TexasAges 12 years+ - NCT01746836RecruitingPhase 2
Ponatinib for CML that didn’t respond to prior pills
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Houston, TexasAges 18 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT04925479RecruitingPhase 1/Phase 2
Testing asciminib dosing and safety for teen CML patients
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
Houston, TexasAges 1–17 - NCT04659616RecruitingPhase 1
Pemigatinib after standard chemo for newly diagnosed AML
This Phase 1 trial studies whether adding pemigatinib after standard “7+3” chemotherapy can improve outcomes in certain newly diagnosed acute myeloid leukemia (AML) patients. It aims to find a safe dose and see how well the drug works in a very specific AML genetic group.
Dallas, TexasAges 18 years+ - NCT06285890RecruitingPhase 1
HC-7366 study for relapsed or refractory AML
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Houston, TexasAges 18 years+ - NCT06448013RecruitingPhase 1
Ziftomenib with chemo for pediatric AML
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
Houston, TexasAges 3–21 - NCT06769490RecruitingPhase 1
Ziftomenib and Quizartinib combination for AML
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Houston, TexasAges 18 years+ - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Houston, TexasAges 18 years+ - NCT05360160RecruitingPhase 1/Phase 2
Oral menin inhibitor plus AML medicines for new or relapsed AML
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Houston, TexasAges 12 years+ - NCT06191978RecruitingPhase 1
Testing venetoclax with decitabine/cedazuridine for pediatric AML
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
Houston, TexasAges 2–18 - NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Houston, TexasAges 18 years+ - NCT05834244RecruitingPhase 1
New and relapsed AML treatment using azacitidine, venetoclax, and NK cells
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Houston, TexasAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax and HMA for older adults with FLT3-mutated AML
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
Houston, TexasAges 18 years+ - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Houston, TexasAges 18 years+
Chronic Myeloid Leukemia trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting chronic myeloid leukemia studies listed above.
- The University of Texas MD Anderson Cancer Center · 21 studies
- University of Texas Southwestern Medical Center · 2 studies
- Baylor College of Medicine
- Ben Taub General Hospital
- Houston Methodist Hospital
What taking part in a chronic myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Chronic Myeloid Leukemia trials in other states
Common questions
- Are there chronic myeloid leukemia clinical trials in Texas?
- Yes. We're currently tracking 65 recruiting chronic myeloid leukemia studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic myeloid leukemia study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic myeloid leukemia studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.